These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 18482837)
1. New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies. Sundriyal S; Viswanad B; Bharathy E; Ramarao P; Chakraborti AK; Bharatam PV Bioorg Med Chem Lett; 2008 Jun; 18(11):3192-5. PubMed ID: 18482837 [TBL] [Abstract][Full Text] [Related]
2. New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. Sundriyal S; Viswanad B; Ramarao P; Chakraborti AK; Bharatam PV Bioorg Med Chem Lett; 2008 Sep; 18(18):4959-62. PubMed ID: 18752947 [TBL] [Abstract][Full Text] [Related]
3. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I). Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators. Kumar R; Mittal A; Ramachandran U Bioorg Med Chem Lett; 2007 Aug; 17(16):4613-8. PubMed ID: 17574414 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2. Usui S; Suzuki T; Hattori Y; Etoh K; Fujieda H; Nishizuka M; Imagawa M; Nakagawa H; Kohda K; Miyata N Bioorg Med Chem Lett; 2005 Mar; 15(6):1547-51. PubMed ID: 15745794 [TBL] [Abstract][Full Text] [Related]
6. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087 [TBL] [Abstract][Full Text] [Related]
7. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. Khanna S; Sobhia ME; Bharatam PV J Med Chem; 2005 Apr; 48(8):3015-25. PubMed ID: 15828840 [TBL] [Abstract][Full Text] [Related]
8. Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Deng G; Liu Z; Ye F; Luo X; Zhu W; Shen X; Liu H; Jiang H Eur J Med Chem; 2008 Dec; 43(12):2699-716. PubMed ID: 18329752 [TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors. Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045 [TBL] [Abstract][Full Text] [Related]
10. 2D QSAR of PPARgamma agonist binding and transactivation. Rücker C; Scarsi M; Meringer M Bioorg Med Chem; 2006 Aug; 14(15):5178-95. PubMed ID: 16650995 [TBL] [Abstract][Full Text] [Related]
11. Lead optimization via high-throughput molecular docking. Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists. Shi Q; Canada EJ; Xu Y; Warshawsky AM; Etgen GJ; Broderick CL; Clutinger CK; Irwin LA; Laurila ME; Montrose-Rafizadeh C; Oldham BA; Wang M; Winneroski LL; Xie C; York JS; Yumibe NP; Zink RW; Mantlo N Bioorg Med Chem Lett; 2007 Dec; 17(24):6744-9. PubMed ID: 18029178 [TBL] [Abstract][Full Text] [Related]
14. Design of antineoplastic agents based on the "2-phenylnaphthalene-type" structural pattern. 4. Synthesis and biological activity of 2-chloro-3-(substituted phenoxy)-1, 4-naphthoquinones and related 5,8-dihydroxy-1,4-naphthoquinones. Chang HX; Chou TC; Savaraj N; Liu LF; Yu C; Cheng CC J Med Chem; 1999 Feb; 42(3):405-8. PubMed ID: 9986711 [TBL] [Abstract][Full Text] [Related]
15. Computational screening of phthalate monoesters for binding to PPARgamma. Kaya T; Mohr SC; Waxman DJ; Vajda S Chem Res Toxicol; 2006 Aug; 19(8):999-1009. PubMed ID: 16918238 [TBL] [Abstract][Full Text] [Related]
16. Focused combinatorial library design based on structural diversity, druglikeness and binding affinity score. Chen G; Zheng S; Luo X; Shen J; Zhu W; Liu H; Gui C; Zhang J; Zheng M; Puah CM; Chen K; Jiang H J Comb Chem; 2005; 7(3):398-406. PubMed ID: 15877468 [TBL] [Abstract][Full Text] [Related]
17. Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. Luksch T; Chan NS; Brass S; Sotriffer CA; Klebe G; Diederich WE ChemMedChem; 2008 Sep; 3(9):1323-36. PubMed ID: 18752222 [TBL] [Abstract][Full Text] [Related]
18. 'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists. Sundriyal S; Bharatam PV Eur J Med Chem; 2009 Jan; 44(1):42-53. PubMed ID: 18448203 [TBL] [Abstract][Full Text] [Related]